Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial

Published:2021-10-29 Issue: Volume: Page:1-12
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Pepin Stephanie¹,Nicolas Jean-François²,Szymanski Henryk³,Leroux-Roels Isabel⁴,Schaum Thomas⁵,Bonten Marc⁶,Icardi Giancarlo⁷^ORCID,Shrestha Anju⁸,Tabar Cynthia¹,

Affiliation:

1. Global Clinical Sciences, Sanofi Pasteur, Marcy L’Etoile, France

2. Clinical Immunology & Allergology Department, Centre Hospitalier Lyon-Sud, Lyon, France

3. Paediatrics, St Hedwig of Silesia Hospital Trzebnica, Prusicka, Trzebnica, Poland

4. Centrum Voor Vaccinologie, Ghent University Hospital, Ghent, Belgium

5. RED-Institut, Oldenburg in Holstein, Germany

6. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

7. Department of Health Sciences, Ospedale Policlinico S. Martino IRCCS, University of Genoa, Genoa, Italy

8. Global Pharmacovigilance, Sanofi Pasteur, Swiftwater, PA, USA

Funder

Sanofi Pasteur

Publisher